Literature DB >> 20020217

Adenosine A(2A) agonist and A(2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation.

Sebastian Michael, Claudia Warstat, Fabien Michel, Luo Yan, Christa E Müller, Karen Nieber.   

Abstract

Adenosine can show anti-inflammatory as well as pro-inflammatory activities. The contribution of the specific adenosine receptor subtypes in various cells, tissues and organs is complex. In this study, we examined the effect of the adenosine A(2A) receptor agonist CGS 21680 and the A(2B)R antagonist PSB-1115 on acute inflammation induced experimentally by 2,4,6-trinitrobenzenesulfonic acid (TNBS) on rat ileum/jejunum preparations. Pre-incubation of the ileum/jejunum segments with TNBS for 30 min resulted in a concentration-dependent inhibition of acetylcholine (ACh)-induced contractions. Pharmacological activation of the A(2A)R with CGS 21680 (0.1-10 microM) pre-incubated simultaneously with TNBS (10 mM) prevented concentration-dependently the TNBS-induced inhibition of the ACh contractions. Stimulation of A(2B)R with the selective agonist BAY 60-6583 (10 microM) did neither result in an increase nor in a further decrease of ACh-induced contractions compared to the TNBS-induced inhibition. The simultaneous pre-incubation of the ileum/jejunum segments with TNBS (10 mM) and the selective A(2B)R antagonist PSB-1115 (100 microM) inhibited the contraction-decreasing effect of TNBS. The effects of the A(2A)R agonist and the A(2B)R antagonist were in the same range as the effect induced by 1 microM methotrexate. The combination of the A(2A)R agonist CGS 21680 and the A(2B)R antagonist PSB-1115 at subthreshold concentrations of both agents found a significant amelioration of the TNBS-diminished contractility. Our results demonstrate that the activation of A(2A) receptors or the blockade of the A(2B) receptors can prevent the inflammation-induced disturbance of the ACh-induced contraction in TNBS pre-treated small intestinal preparations. The combination of both may be useful for the treatment of inflammatory bowel diseases.

Entities:  

Keywords:  A2AR agonist; A2BR antagonist; Adenosine receptors; Inflammation; Rat; Small intestine; TNBS

Year:  2009        PMID: 20020217      PMCID: PMC2837822          DOI: 10.1007/s11302-009-9174-y

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  44 in total

1.  T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.

Authors:  Anne R Gocke; Petra D Cravens; Li-Hong Ben; Rehana Z Hussain; Sara C Northrop; Michael K Racke; Amy E Lovett-Racke
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

2.  TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis.

Authors:  V Kolachala; V Asamoah; L Wang; T S Obertone; T R Ziegler; D Merlin; S V Sitaraman
Journal:  Cell Mol Life Sci       Date:  2005-11       Impact factor: 9.261

Review 3.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 4.  Targeting adenosine A2A receptors in Parkinson's disease.

Authors:  Michael A Schwarzschild; Luigi Agnati; Kjell Fuxe; Jiang-Fan Chen; Micaela Morelli
Journal:  Trends Neurosci       Date:  2006-10-09       Impact factor: 13.837

5.  Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury.

Authors:  Chun-Xiao Sun; Hongyan Zhong; Amir Mohsenin; Eva Morschl; Janci L Chunn; Jose G Molina; Luiz Belardinelli; Dewan Zeng; Michael R Blackburn
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

6.  Attenuation of gastric mucosal inflammation induced by aspirin through activation of A2A adenosine receptor in rats.

Authors:  Masaru Odashima; Michiro Otaka; Mario Jin; Koga Komatsu; Isao Wada; Youhei Horikawa; Tamotsu Matsuhashi; Natsumi Hatakeyama; Jinko Oyake; Reina Ohba; Sumio Watanabe; Joel Linden
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

7.  Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.

Authors:  Luo Yan; Christa E Müller
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

8.  A2B adenosine receptor gene deletion attenuates murine colitis.

Authors:  Vasantha L Kolachala; Matam Vijay-Kumar; Guillaiume Dalmasso; Dan Yang; Joel Linden; Lixin Wang; Andrew Gewirtz; Katya Ravid; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

9.  Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia.

Authors:  Andras Bilkei-Gorzo; Osama M Abo-Salem; Alaa M Hayallah; Kerstin Michel; Christa E Müller; Andreas Zimmer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-10       Impact factor: 3.000

10.  Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion.

Authors:  Atsushi Kuno; Stuart D Critz; Lin Cui; Victoriya Solodushko; Xi-Ming Yang; Thomas Krahn; Barbara Albrecht; Sebastian Philipp; Michael V Cohen; James M Downey
Journal:  J Mol Cell Cardiol       Date:  2007-05-24       Impact factor: 5.000

View more
  9 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

Review 2.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

3.  Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.

Authors:  Mohamad Wessam Alnouri; Stephan Jepards; Alessandro Casari; Anke C Schiedel; Sonja Hinz; Christa E Müller
Journal:  Purinergic Signal       Date:  2015-07-01       Impact factor: 3.765

4.  Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.

Authors:  Ali El-Tayeb; Sebastian Michael; Aliaa Abdelrahman; Andrea Behrenswerth; Sabrina Gollos; Karen Nieber; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

Review 5.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

6.  Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Authors:  Noam Rudich; Katya Ravid; Ronit Sagi-Eisenberg
Journal:  Front Immunol       Date:  2012-06-04       Impact factor: 7.561

7.  MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting.

Authors:  Ting Tian; Yu Zhou; Xiao Feng; Shicai Ye; Hao Wang; Weiyun Wu; Wenkai Tan; Caiyuan Yu; Juxiang Hu; Rong Zheng; Zonghao Chen; Xinyu Pei; Hesheng Luo
Journal:  Sci Rep       Date:  2016-08-01       Impact factor: 4.379

Review 8.  Control of Gut Inflammation by Modulation of Purinergic Signaling.

Authors:  Marta Vuerich; Samiran Mukherjee; Simon C Robson; Maria Serena Longhi
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

9.  An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway.

Authors:  Tianhua Ren; Ting Tian; Xiao Feng; Shicai Ye; Hao Wang; Weiyun Wu; Yumei Qiu; Caiyuan Yu; Yanting He; Juncheng Zeng; Junwei Cen; Yu Zhou
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.